Scribe Therapeutics

Attending the Leerink Partners Global Healthcare Conference in Miami this week? Our CEO Benjamin Oakes and CFO David Parrot will be available for one-on-one meetings with investors tomorrow. Interested in connecting? Reach out to us via our website: https://lnkd.in/gpBrcc4B Read our press release to learn more: https://lnkd.in/geYY-BCF #CRISPR #CRISPRbyDesign #GeneticMedicine

We’re excited to share the latest advancements on our ELXR epigenome modifying technology at this year’s Keystone Symposia on Molecular & Cellular Biology's Precision Genome Engineering conference. Check out the highlights below and in our press release: https://lnkd.in/gV5Hmi3k ?? A high throughput screen of >30,000 diverse repressor domains identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain potency ?? These repressor domains have been utilized to enhance ELXRs, making them more potent than current Cas9-based repressors ?? ELXRs offer a promising epigenetic editing approach to treat dyslipidemias with best-in-class efficacy at lower therapeutic doses By leveraging our CRISPR by Design approach to engineer novel and potent epigenetic editors, we are unlocking unprecedented potential to deliver safer and more effective therapies for cardiometabolic disease and transforming the future of human health. #EpigeneticEditing #Epigenetics #CRISPRbyDesign

Don’t miss Principal Scientist Jason Fernandes’ late-breaking talk today at Keystone Symposia on Molecular & Cellular Biology’s “Precision Genome Engineering: Translating the Human Genome to the Clinic” conference! Details below: ?? Symposia Spotlight ?? Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates ?? 3:00-4:30 p.m. GMT ?? INEC Main Auditorium

#CRISPR can change the world—without editing your DNA. In The Economist’s latest Technology Quarterly report, “The age of CRISPR,” epigenetic editing is highlighted as a transformative technology that offers a gentler form of gene editing. Thanks to Ida Emilie Steinmark for featuring Scribe and our work to develop genetic medicines that are effective and safe enough for broad patient populations, starting with cardiometabolic disease. Steinmark writes: "Benjamin Oakes, the boss of Scribe Therapeutics, a Californian biotech firm, sees a future in which ???????????????????? ?????????????? ?????????????? ???????? ?????????????? ?? ?????? ????????, ?????? ?????? ???????????????????? ?????????????? ?????????? ?????????????? ?????? ?????????????? ?????????????? ???? ??????????????. ????????????’?? ???????????????????? ???????????? ?????? ?????????? ?? ???????? ?????????????? ?????????????????? ?????????????????????? ???? ??????????????. 'We can essentially modify your genome so you’re no longer producing risk factors for cardiometabolic disease. And maybe every five years, or every ten years, you need to come back for a booster dose.'" If you’re interested in learning more about how epigenetic editing is shaping the future of medicine and the exciting science behind our epigenetic editors (ELXRs): ?? Read The Economist’s article here: https://lnkd.in/gChR6n4m ?? Check out our upcoming presentation on our ELXR technology at Keystone Symposia on Molecular & Cellular Biology taking place tomorrow, Tuesday, March 4 between 3:00-4:30 p.m. GMT: https://lnkd.in/geYY-BCF? ?? Visit our website: https://www.scribetx.com/

?? Did you know that elevated LDL cholesterol (LDL-C) levels can increase risk for cardiovascular disease, the leading cause of death worldwide? As we observe #HeartMonth, we’re reminded of the importance of heart health and the ongoing fight against cardiometabolic disease (CMD). With heart disease affecting millions globally, Scribe is engineering genetic medicines that are potent and safe enough to become the standard of care for lowering LDL-C and revolutionize the treatment of CMD. We are focused on unlocking the potential of #CRISPR to target the underlying drivers of this disease and ultimately improve the quality of life for patients. Learn more about the importance of advancing better therapies for cardiometabolic disease by visiting our website: https://lnkd.in/gu93HgK3

Meet our Scribe team at the following March events: 1?? “Precision Genome Engineering: Translating the Human Genome to the Clinic” conference hosted by Keystone Symposia on Molecular & Cellular Biology: Jason Fernandes, Principal Scientist at Scribe, will present a late-breaking talk titled “Engineering of Next Generation Epigenetic Editors for Enhanced Durable Repression in Non-Human Primates.” This presentation will showcase the latest developments in our proprietary epigenetic editing technology, ELXR, on Tuesday, March 4 between 3:00-4:30 p.m. GMT. 2?? Leerink Partners Global Healthcare Conference: Our CEO Benjamin Oakes and CFO David Parrot will be available for one-on-one meetings with investors on Tuesday, March 11 in Miami. For more details, read our press release ?? https://lnkd.in/geYY-BCF

?? Imagine a future where medicine is: ? ?? ????????????????????????: Calibrating your genome to prevent common diseases. ? ????????????????????: Freeing you from inherited conditions and lifelong treatments. ? ??????????????????: Making genetic therapies safe and accessible for all. ? At Scribe, we’re rewriting the story of disease because genetic predisposition shouldn’t dictate your health destiny. We’re on a mission to build CRISPR-based therapeutics that are safe and potent enough to transform everyone’s lifetime risk for disease. ? ??? Our approach? CRISPR by Design. Every step is taken with meticulous precision to engineer therapeutics that are not only effective but also safe. It is all about purposeful innovation, driven by intentional design and a commitment to excellence.? ? ?? Our portfolio is designed to maximize patient impact. We’re starting with purpose-built CRISPR therapies to tackle cardiometabolic disease, the world’s leading cause of death. And this is just the beginning of our mission to make a lasting and meaningful change. ? As our Founder & CEO, Benjamin Oakes, says: “We’re dedicated to making CRISPR safe and effective enough for broad use. We envision a world in which we all take control of our own health destiny – not just inherit it.” ? Join us on this journey and see how Scribe is reshaping medicine by engineering a healthier tomorrow by visiting our new website at scribetx.com, developed in collaboration with the talented team at Bunsen.

What does the future hold for for #biotech? Labiotech.eu interviewed our Chief Business Officer Svetlana Lucas about advancements in #CRISPR engineering and the potential for genetic medicine “to drive a paradigm shift in how we approach and treat not just rare disease, but chronic diseases as well.” On collaborations between biotech and pharma, she highlighted that “global partnerships will accelerate this effort to move breakthrough science from bench to bedside and tangibly change our standard of care for the better.” Check out her industry insights on gene editing, epigenetic modification, and more here: https://buff.ly/4he6Wob #CRISPRbyDesign #GeneEditing #EpigeneticEditing #Epigenetics

Who’s ready for J.P. Morgan? We're looking forward to an action-packed week. Check out some of a16z bio + health's portfolio companies presenting at and around the conference. #JPM2025 Benjamin Oakes @ Scribe Therapeutics Daphne Koller @ insitro Sean Duffy @ Omada Health Arif Nathoo @ Komodo Health Elizabeth Schwarzbach @ BigHat Biosciences Shyamali Choudhury @ Pomelo Care Mark DePristo @ BigHat Biosciences Josh Mandel-Brehm @ CAMP4 Therapeutics

We’re pleased to announce the achievement of a success milestone for one of the targets in our research collaboration with Sanofi to develop in vivo #CRISPR-based therapeutics. Read the highlights below and in our press release (https://lnkd.in/gGTGDuxR). For more updates on Scribe, #JPM25 attendees can tune into our presentation by CEO Benjamin Oakes starting later today at 4:30pm PT. ?? Scribe is eligible to receive over $1.2 billion across all programs in milestone payments for the achievement of certain research, development, regulatory, and commercial milestones. ?? This milestone further demonstrates the strength of Scribe’s CRISPR by Design? approach for optimizing its CRISPR-based platforms and assets. ?? It builds upon our companies’ initial research collaboration to address oncology indications in 2022, followed by an expansion in 2023 to advance in vivo medicines for genomic diseases. #CRISPRbyDesign #GeneEditing #EpigeneticEditing #Epigenetics #Biotech #JPM2025